0 14 Interleukin-10 Interleukin-10 NNP 15 18 and and CC 19 31 transforming transform VBG 32 38 growth growth NN 39 50 factor-beta factor-beta NN 51 59 promoter promoter NN 60 73 polymorphisms polymorphism NNS 74 76 in in IN 77 86 allergies allergy NNS 87 90 and and CC 91 97 asthma asthma NN 97 98 . . . 100 114 Interleukin-10 Interleukin-10 NNP 115 116 ( ( ( 116 121 IL-10 IL-10 NNP 121 122 ) ) ) 123 126 and and CC 127 139 transforming transform VBG 140 146 growth growth NN 147 153 factor factor NN 154 158 beta beta NN 159 160 ( ( ( 160 168 TGF-beta TGF-beta NNP 168 169 ) ) ) 170 173 are be VBP 174 184 inhibitory inhibitory JJ 185 188 for for IN 189 190 B B NNP 191 194 and and CC 195 196 T t NN 197 202 cells cell NNS 202 203 , , , 204 207 IgE IgE NNP 208 218 production production NN 218 219 , , , 220 223 and and CC 224 228 mast mast NN 229 233 cell cell NN 234 247 proliferation proliferation NN 247 248 , , , 249 252 and and CC 253 257 they they PRP 258 264 induce induce VBP 265 274 apoptosis apoptosis NN 275 277 in in IN 278 289 eosinophils eosinophil NNS 289 290 . . . 291 296 These these DT 297 306 cytokines cytokine NNS 307 310 are be VBP 311 320 therefore therefore RB 321 330 candidate candidate NN 331 336 genes gene NNS 337 342 which which WDT 343 348 could could MD 349 359 contribute contribute VB 360 362 to to TO 363 366 the the DT 367 378 development development NN 379 381 of of IN 382 388 asthma asthma NN 389 391 or or CC 392 401 allergies allergy NNS 401 402 . . . 403 405 We we PRP 406 418 investigated investigate VBD 419 422 the the DT 423 433 hypothesis hypothesis NN 434 438 that that IN 439 450 polymorphic polymorphic JJ 451 462 nucleotides nucleotide NNS 463 469 within within IN 470 473 the the DT 474 479 IL-10 IL-10 NNP 480 483 and and CC 484 492 TGF-beta TGF-beta NNP 493 497 gene gene NN 498 507 promoters promoter NNS 508 513 would would MD 514 518 link link VB 519 521 to to TO 522 525 the the DT 526 536 expression expression NN 537 539 of of IN 540 549 allergies allergy NNS 550 553 and and CC 554 560 asthma asthma NN 560 561 . . . 562 565 DNA DNA NNP 566 571 taken take VBN 572 576 from from IN 577 585 families family NNS 586 590 with with IN 591 593 an an DT 594 603 asthmatic asthmatic JJ 604 611 proband proband NN 612 615 was be VBD 616 624 examined examine VBN 625 628 for for IN 629 633 base base NN 634 643 exchanges exchange NNS 644 646 by by IN 647 662 single-stranded single-stranded JJ 663 677 conformational conformational JJ 678 690 polymorphism polymorphism NN 691 692 ( ( ( 692 696 SSCP SSCP NNP 696 697 ) ) ) 697 698 . . . 699 701 We we PRP 702 714 demonstrated demonstrate VBD 715 718 the the DT 719 727 presence presence NN 728 730 of of IN 731 732 a a DT 733 745 polymorphism polymorphism NN 746 748 in in IN 749 752 the the DT 753 761 promoter promoter NN 762 768 region region NN 769 771 of of IN 772 775 the the DT 776 781 IL-10 il-10 NN 782 786 gene gene NN 787 790 and and CC 791 795 four four CD 796 798 in in IN 799 802 the the DT 803 811 TGF-beta TGF-beta NNP 812 816 gene gene NN 817 826 promoters promoter NNS 827 828 ( ( ( 828 829 3 3 CD 830 832 in in IN 833 842 TGF-beta1 TGF-beta1 NNP 843 846 and and CC 847 848 1 1 CD 849 851 in in IN 852 861 TGF-beta2 tgf-beta2 NN 861 862 ) ) ) 862 863 . . . 864 867 The the DT 868 873 IL-10 IL-10 NNP 874 878 gene gene NN 879 891 polymorphism polymorphism NN 892 895 was be VBD 896 897 a a DT 898 904 C-to-A C-to-A NNP 905 913 exchange exchange NN 914 917 571 571 CD 918 922 base base NN 923 928 pairs pair NNS 929 937 upstream upstream JJ 938 942 from from IN 943 946 the the DT 947 958 translation translation NN 959 964 start start NN 965 969 site site NN 970 973 and and CC 974 977 was be VBD 978 985 present present JJ 986 993 between between IN 994 1003 consensus consensus NN 1004 1011 binding binding NN 1012 1021 sequences sequence NNS 1022 1025 for for IN 1026 1029 Sp1 sp1 NN 1030 1033 and and CC 1034 1042 elevated elevated JJ 1043 1048 total total JJ 1049 1054 serum serum NN 1054 1055 . . . 1056 1060 This this DT 1061 1073 polymorphism polymorphism NN 1074 1077 was be VBD 1078 1088 associated associate VBN 1089 1093 with with IN 1094 1102 elevated elevated JJ 1103 1108 total total JJ 1109 1114 serum serum NN 1115 1118 IgE ige NN 1119 1121 in in IN 1122 1130 subjects subject NNS 1131 1144 heterozygotic heterozygotic JJ 1145 1147 or or CC 1148 1159 homozygotic homozygotic JJ 1160 1163 for for IN 1164 1168 this this DT 1169 1173 base base NN 1174 1182 exchange exchange NN 1183 1184 ( ( ( 1184 1185 p p NN 1186 1187 < < JJR 1188 1193 0.009 0.009 CD 1193 1194 ) ) ) 1194 1195 . . . 1196 1199 The the DT 1200 1204 base base NN 1205 1213 exchange exchange NN 1214 1216 at at IN 1217 1221 -509 -509 CD 1222 1223 ( ( ( 1223 1227 from from IN 1228 1231 the the DT 1232 1245 transcription transcription NN 1246 1256 initiation initiation NN 1257 1261 site site NN 1261 1262 ) ) ) 1263 1265 in in IN 1266 1269 the the DT 1270 1278 TGF-beta TGF-beta NNP 1279 1287 promoter promoter NN 1288 1292 also also RB 1293 1299 linked link VBN 1300 1302 to to TO 1303 1311 elevated elevated JJ 1312 1317 total total JJ 1318 1321 IgE ige NN 1322 1323 ( ( ( 1323 1324 p p NN 1325 1326 < < SYM 1327 1331 0.01 0.01 CD 1331 1332 ) ) ) 1332 1333 . . . 1334 1338 This this DT 1339 1351 polymorphism polymorphism NN 1352 1363 represented represent VBD 1364 1365 a a DT 1366 1372 C-to-T c-to-t JJ 1373 1377 base base NN 1378 1386 exchange exchange NN 1387 1392 which which WDT 1393 1400 induced induce VBD 1401 1402 a a DT 1403 1406 YY1 yy1 NN 1407 1416 consensus consensus NN 1417 1425 sequence sequence NN 1426 1429 and and CC 1430 1432 is be VBZ 1433 1440 present present JJ 1441 1443 in in IN 1444 1445 a a DT 1446 1452 region region NN 1453 1455 of of IN 1456 1459 the the DT 1460 1468 promoter promoter NN 1469 1479 associated associate VBN 1480 1484 with with IN 1485 1493 negative negative JJ 1494 1507 transcription transcription NN 1508 1518 regulation regulation NN 1518 1519 . . .